vTv Therapeutics Inc (VTVT NASDAQ) stock market data APIs
$35.903
0.53(1.5%)
as of March 20, 2026
Try our APIs with
free plan!
vTv Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Prev. Close
35.903
Open
36.4284
High
37.8663
Low
35.4455
52 wk Range
14-44
Market Cap
142 M
Shares Outstanding
3 939 K
Revenue
17 000
EPS
-0.58
Beta
0.432
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with vTv Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get vTv Therapeutics Inc data using free add-ons & libraries
Get vTv Therapeutics Inc Fundamental Data
vTv Therapeutics Inc Fundamental data includes:
- Net Revenue: 17 000
- EBITDA: -32 792 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-12-31
- EPS/Forecast: -1.088
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
vTv Therapeutics Inc News
New
vTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin Advancements
vTv Therapeutics Inc. (NASDAQ:VTVT) is one of the best hot stocks to buy according to analysts. On March 10, vTv Therapeutics reported its financial results for Q4 and the full-year 2025. For 2025, th...
VTv Therapeutics Posts Wider FY25 Loss, Advances Phase 3 CATT1 Trial For Type 1 Diabetes
(RTTNews) - vTv Therapeutics Inc. (VTVT) reported fourth-quarter and full-year 2025 financial results and outlined continued progress across its late-stage diabetes pipeline, led by, Cadisegliatin the...
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026 Strengthened balance ...
vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737
vTv Therapeutics Inc. (NASDAQ:VTVT) is one of the most promising micro-cap stocks according to analysts. On February 2, vTv Therapeutics expanded its partnership with Newsoara Biopharma Co. Ltd., tran...
Get vTv Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
